Gervasini Guillermo, Caballero Maria J, Carrillo Juan A, Benitez Julio
Department of Medical and Surgical Therapeutics, Division of Pharmacology, Medical School, University of Extremadura, Av. Elvas s/n, 06071 Badajoz, Spain.
ISRN Pharmacol. 2013;2013:792456. doi: 10.1155/2013/792456. Epub 2013 Feb 13.
The goal of this study was to assess in human liver microsomes the inhibitory capacity of commonly used antipsychotics on the most prominent CYP450 drug metabolizing enzymes (CYP1A2, CYP2C9, CYP2D6, and CYP3A). Chlorpromazine was the only antipsychotic that inhibited CYP1A2 activity (IC50 = 9.5 μ M), whilst levomepromazine, chlorpromazine, and thioridazine significantly decreased CYP2D6-mediated formation of 1'-hydroxybufuralol (IC50 range, 3.5-25.5 μ M). Olanzapine inhibited CYP3A-catalyzed production of 1', and 4'-hydroxymidazolam (IC50 = 14.65 and 42.20 μ M, resp.). In contrast, risperidone (IC50 = 20.7 μ M) and levomepromazine (IC50 = 30 μ M) showed selectivity towards the inhibition of midazolam 1'-hydroxylation reaction, and haloperidol did so towards 4'-hydroxylation (IC50 of 2.76 μ M). Thioridazine displayed a Ki of 1.75 μ M and an inhibitory potency of 1.57 on CYP2D6, suggesting a potential to induce in vivo interactions. However, with this exception, and given the observed Ki values, the potential of the assayed antipsychotics to produce clinically significant inhibitions of CYP450 isoforms in vivo seems limited.
本研究的目的是在人肝微粒体中评估常用抗精神病药物对最主要的CYP450药物代谢酶(CYP1A2、CYP2C9、CYP2D6和CYP3A)的抑制能力。氯丙嗪是唯一抑制CYP1A2活性的抗精神病药物(IC50 = 9.5 μM),而左美丙嗪、氯丙嗪和硫利达嗪显著降低CYP2D6介导的1'-羟基布非洛尔的形成(IC50范围为3.5 - 25.5 μM)。奥氮平抑制CYP3A催化的1'和4'-羟基咪达唑仑的生成(IC50分别为14.65和42.20 μM)。相比之下,利培酮(IC50 = 20.7 μM)和左美丙嗪(IC50 = 30 μM)对咪达唑仑1'-羟基化反应表现出抑制选择性,而氟哌啶醇对4'-羟基化表现出抑制选择性(IC50为2.76 μM)。硫利达嗪对CYP2D6的Ki为1.75 μM,抑制效力为1.57,表明其在体内有诱导相互作用的潜力。然而,除了这种情况,鉴于观察到的Ki值,所检测的抗精神病药物在体内对CYP450同工酶产生临床显著抑制的潜力似乎有限。